RELEASE OF CARTILAGE MUCOPOLYSACCHARIDE-DEGRADING NEUTRAL PROTEASE FROM HUMAN LEUKOCYTES by Oronsky, A. et al.
RELEASE  OF  CARTILAGE  MUCOPOLYSACCHARIDE-DEGRADING 
NEUTRAL  PROTEASE  FROM  HUMAN  LEUKOCYTES 
B,' A. ORONSKY,*  L.  IGNARRO,:~  AND R.  PERPER,§ 
(From  The  Research  Department,  Pharmaceuticals Division,  CIBA-Geigy  Corporation, 
Ardsley, New York 10502) 
(Received for publication 12 April 1973) 
The  granule  fraction  of  human  leukocytes  contains  neutral  protease  capable  of 
degrading  the  noncollagenous,  chondromucoprotein  matrix  of  intact  rabbit  ear 
cartilage (1). In order to ascertain the mechanism by which these enzymes gain access 
to extracellular tissue, it is important to determine whether cells can release neutral 
protease under physiologic conditions. Human leukocytes have been reported to re- 
lease lysosomal acid hydrolases during  the  process of  phagocytosis without  a  con- 
comitant loss of cell viability. Release has been observed when cells phagocytize latex 
particles,  monosodium  urate  crystals,  zymosan,  and  antigen/antibody  complexes 
(2-5). This process is enhanced when  cells attempt to phagocytoze such substances 
fixed to a solid support (nonphagocytic enzyme release) (6). 
In rheumatoid arthritis antigen/antibody complexes of the IgM and IgG anti-IgG 
type have been demonstrated in synovial fluid and as cytoplasmic inclusion in leuko- 
cytes which are chemotactically attracted to sites of inflammation (7-9). It is there- 
fore possible that the cartilage destruction in rheumatoid arthritis could be a  direct 
result  of  the  release of  deleterious  enzymes  during  the  process  of  phagocytosis of 
antigen/antibody complexes. 
In this report we demonstrate that human leukocytes, in  physiologic buffer, 
in the presence of either suspended or fixed aggregated human gamma globulin 
(AHGG),  1 release neutral protease(s)  that  are  capable of degrading the non- 
collagenous, chrondromucoprotein matrix of cartilage. In  addition, gold thio- 
malate  and  colchicine,  both  clinically active  anti-inflammatory agents,  were 
tested  for  their  capacity  to  inhibit  nonphagocytic  release  of  human  neutral 
protease and/or protease activity directly. Colchicine inhibited the nonphago- 
cytic release of human  neutral protease.  Conversely, gold thiomalate and iso- 
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logous  human  serum  (10%)  inhibited directly  the protease  activity  without 
influencing enzyme release. 
Materials  and Methods 
Preparation of  Viable Human  Leukocytes and  Leukocyte Granule Fraction.--A  leukocyte- 
enriched fraction, obtained from the peripheral blood of healthy rheumatoid factor negative 
(latex agglutination) donors, was isolated within 1 h of venipuncture, by dextran sedimentation 
as described previously (10). The mixed leukocyte suspension was washed once with Hanks' 
balanced salt  solution  (Hanks' BSS)  containing 1%  glucose  and  resuspended in  the same 
medium. All incubations were started 3 h after collection of blood. "['he cells had a viability of 
>99% as judged by Trypan blue dye exclusion and on the average consisted of 40% neutro- 
phils, 50% lymphocytes, 6% monocytes, 3% eosinophils, and 1% basophi]s. The granule frac- 
tion from human leukocytes was prepared as previously described (11). The granule fraction 
was resuspended in Hanks' BSS (pH 7.4) and subjected to 10 freeze-thaw cycles using a dry 
ice-acetone mixture. After the final  thaw, the suspension was centrifuged at 15,000 X  g for 
25 rain at 4°C and the supernatant was used immediately. 
Preparation of 35S-Labeled Rabbil Ear Cartilage.--The  preparation of rabbit ear cartilage 
labeled with 35S and the experiments defining the specificity of mucopolysaccharide labeling 
have been described in detail in a preceding report (1). Disks (3.0 mm diameter) of 35S-labeled 
cartilage were either used fresh or stored at --70°C for 1-3 wk. Frozen specimens  were thawed 
at 4°C and used immediately. In each experiment cartilage from the same rabbit was used for 
both control and experimental conditions. Total '~5S in the cartilage was determined by dis- 
solving the tissue in 2.0 ml of hot concentrated hydrochloric acid and analyzing 0.1-0.2 ml 
aliquots for  ~S activity in a  Packard  Tri-Carb  liquid  scintillation spectrometer (Parkard 
Instrument Co. Inc., Downers Grove, Ill.). 
Preparation of A HGG.--Human gamma globulin (HGG)  (Fraction II, Miles Laboratories 
Inc., Kankakee, Ill.) was heat aggregated by first dissolving 56 mg in 6.0 ml of phosphate- 
buffered saline (pH 6.4) and heating at 63°C for 20 min. An additional 100 mg HGG was dis- 
solved and the incubation was continued for 20 min at 63°C. The precipitate (AHGG) was 
suspended in 2.5 ml of Hanks' BSS with glucose and a homogenous suspension was prepared 
with a Potter Elvehjem homogenizer (Potter Instrument Co. Inc., Melville, N. Y.)  equipped 
with a Teflon pestle. The final  suspension contained 20 mg/ml of protein and was used im- 
mediately. Non heat-aggregated HGG was prepared by making a  2c)~ solution of HGG in 
Hanks' BSS with glucose. 
Incubation Conditions.-- 
Nonphagocytic enzyme rdease: A single layer of labeled cartilage disks was incubated in 5 ml 
Ehrlenmeyer flasks, containing excess AHGG or HGG (1.0 ml per 20 cartilage disks), at 37°C 
for 20 rain.  Each disk was then removed from the incubation medium with thumb forceps and 
rinsed (Hanks' BSS with glucose)  free of excess gamma globulin.  Depending upon the experi- 
ment, a single layer of 5-10 cartilage disks was placed in a 19 )< 5] mm fiat bottom vial which 
was incubated in an oscillating water bath (50 oscillations/rain) at 37°C.  In all experiments 
1.5 ml  of human leukocyte cell suspensions were added. The cell concentration and time of 
incubation were varied to obtain optimum conditions for enzyme release. The final  method 
consisted of a 4 h incubation with five cartilage disks in 1.5 ml of cell suspension containing 
a total of 5 )<  106 leukocytes. After incubation 0.5 ml aliquots of medium from each vial were 
removed and prepared for liquid scintillation counting as described previously (1).  In most 
experiments, 0.2  ml  aliquots  of  supernatant  (obtained after  centrifugation of medium  at 
900 X g for 10 rain at 4°C) were assayed for ~-glucuronidase (3-G) activity. At the termination 
of incubations, 98% of the cells layered at the bottom of the vials were viable as ascertained 
by dye exclusion.  For additional confirmation of cell viability, lactic dehydrogenase (LDH) 
activity of supernatants was estimated. Triplicate samples were used for the control and ex- 
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In certain experiments gold sodium  thiomalate (Merck,  Sharpe,  and Dohme  of Canada 
Ltd., Montreal, Canada), colchicine (Sigma Chemical Co., St. Louis, Mo.), and 10% isologous 
human serum were added to the incubation medium. 
Phagocytic enzyme release: 5 million human leukocytes,  suspended in 1.5 ml of Hanks' BSS 
with glucose, containing 2% AHGG, 2% HGG or buffer. After incubation for 2 h  at 37°C 
in an oscillating water  bath (50  oscillations/rain), the  cell  suspension  was sedimented  by 
centrifugation (900 X  g for 10 min)  at 4°C. Aliquots of the supernatant were  assayed for 
both LDH and ~-G activity, and 1.0  1.5 ml of supernatant was  incubated with five carti- 
lage disks as described  above.  After an additional 4 h,  0.5 ml aliquots of medium were re- 
moved for 35S determination. 
Enzyme Assays.--13-G and LDH assays were performed on the supernatants from experi- 
ments dealing with phagocytic and nonphagocytic enzyme release, fl-G activity was assayed 
by the method of Gianetto and DeDuve using phenolphthalein glucuronide as substrate (12). 
Aliquots (0.2 ml)  of supernatants were incubated in 3.0 ml of 0.1 M  sodium citrate buffer 
(pH 4.8), containing 5 mg of substrate, at 37°C for 18 h. LDH assays were performed by the 
method described  by Bergmeyer et al. (13) using/3-diphosphopyridine nucleotide (disodium 
salt, reduced form) as substrate. Enzyme activity was quantitated by determining the average 
change in optical density (366 nm) per minute during 3 min of incubation. 
RESULTS 
Eflect  of  Number  of  Leukocytes  and  Time  of  Incubalion  on  Nonphagocytic 
Release  of  Enzymes  from  Huma*~  Leukocytes.--Experiments  with  varying 
numbers of human ]eukocytes were performed using a  standard 4 h  incubation 
(37°C)  in Hanks' ]~SS  (pH  7.4)  containing 1%  glucose. Triplicate determina- 
tions were made with each cell concentration overlying five cartilage disks. The 
results given in Fig. 1 indicate that,  between  concentrations of 0.5  X  106  and 
10 ><  106  leukocytes, there was  a  concentration-dependent release of both  3~S 
and/3-G into  the incubation medium when  cells were incubated with AHGG- 
coated cartilage. In other experiments, using up to 40  X  106 cells, no further 3~S 
release  occurred.  Essentially no  release of 35S  or/3-G  occurred when  AHGG- 
coated cartilage disks were incubated in the absence of leukocytes. Although 
not shown in Fig. 1, less than 8% of total LDH  activity was released with any 
of  the  cell  concentrations  used.  In  addition,  dye  exclusion  studies  indicated 
that,  at  all  the  cell concentrations  used,  greater  than  96%  of the  cells were 
capable of excluding Trypan blue. 
Release of 3~S  with  10  )<  106  cells represented  approximately 58%  (9,454 
cpm)  of  the  total  available 3~S, since  HC1  hydrolysis of five  cartilage pieces 
released 16,300  cpm. The/5-G re}eased  from the same  number of  cells (10  >( 
106) accounted for 40 %  of the total enzyme activity in the cell lysate (legend, 
Fig.  1). Although there was  a  parallelism between the absolute amount of 35S 
and/3-G release, the percentage of the total 35S released from cartilage increased 
with cell number, whereas the percentage of total ~3-G decreased as cell numbers 
increased. Release of 35S  was  cumulative indicating that  the enzyme  causing 
35S release remained active and available to degrade substrate. When the time 
of incubationwas varied under conditions where the number of leukocytes (5)< 
108 ) and the amount of cartilage remained constant, maximum marker enzyme 
release (fl-G) occurred at 2 h, whereas, there was a linear increase in 35S release 464  RELEASE  OF NEUTRAL  PROTEASE  FRO~I HUMAN  LEUKOCYTES 
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FIo. 1. Relationship  between the number of human leukocytes and nonphagocytic enzyme 
release. Five cartilage disks were incubated at 37°C with varying numbers of human leukocytes 
for 4 h at pH 7.4. Release of ~5S cpm is a measure of neutral protease activity and OD values 
(540 rim) define ~-G activity. Total 35S per sample was 16,000 cpm./~-G release from cartilage 
coated with AHGG during a 4 h incubation was 0.01 OD U, while ass release was 320 cpm. 
Total ~-G activity in cell lysates of 0.5, 1.0, 5.0, and 10.0 X 106 cells was 0.06, 0.11, 0.52, and 
1.00D U, respectively. Each point represents the Mean  ±SEM of three separate determina- 
tions.  Symbols:  A--A, release of /3-G from  intact cells in  the presence  of AHGG-coated 
cartilage; •--0,  release of ass from intact cells in the presence of AHGG-coated cartilage. 
through  4 h  (Fig.  2).  During  the  course  of  these  experiments  there  was  no 
significant release of LDH into the incubation medium. 
Analysis of the Spec¢ficily of Enzyme Release.--In the experiments illustrated 
in Figs. 1 and 2, the cartilage was preincubated with AHGG. In order to define 
the  specificity of AHGG  in  causing  nonphagocytic  enzyme  release,  cartilage 
was also preincubated with buffer, 2 % HGG or 2 % AHGG (HGG protein). The 
results in Fig. 3 indicate that 5 X  106 leukocytes caused the release of significant 
amounts  of 3~S and fl-G only when  cartilage was precoated with AHGG. Un- 
coated cartilage and cartilage coated with HGG  released 3,000-4,500  cpm.  In 
contrast to this, the human leukocytes provoked the release of 13,300 cpm from 
cartilage coated with AHGG. In all instances, release of fl-G activity paralleled 
release of :~aS. Less than 8 %  of the total LDH contained in 5  X  106 leukocytes 
was released into the incubation medium (Fig. 3). 
Three  concentrations  of gold  thiomalate  and  colchicine in  triplicate  tubes 
were  included in  the incubation media of 5  X  106  leukocytes and  opsonized 
(AHGG)  ~sS-labeled cartilage disks. In Table I  it can be seen  that release of A. ORONSKY~  L. IGNARR0~ AND  R. PERPER  465 
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FIG.  2.  Relationship of  incubation time to  nonphagocytic enzyme release from  human 
leukocytes. Leukocytes (5  X  106) were incubated with five cartilage disks for 4 h  (37°C)  at 
pH 7.4. Total 3sS per sample was 16,800 cpm, and release of 3~S by lysates of 5  X  106 cells 
was 9,447  cpm. Total/3-G activity in the lysate of 5  X  106 cells was 0.55 OD U  (540 nm). 
The lysates also caused a change in OD/min (366 nm) for lactic dehydrogenase of 0.331  OD 
U.  Each  point  represents  the  Mean  -4-SEM  of  three  separate  determinations.  Symbols: 
A--A,  release of ~-G from intact cells in the presence of AHGG-coated cartilage;  C)--O, 
release of 35S from cartilage coated with AHGG (no cells); •--•,  35S release in the presence 
of 5  X  106 human leukocytes. I--I,  release of LDH from intact cells in the presence of 
AHGG-coated cartilage. 
¢/-G was unaffected by concentrations of 10-4M,  10-SM, or 10-6M gold, whereas 
a  concentration-dependent inhibition of cartilage degradation occurred (85 %, 
55%,  and  33%,  respectively). In  contrast  to  this,  colchicine, at  10-4M  and 
10-~M, inhibited the release of both fl-G and 35S. In order to analyze the dif- 
ferential effects of gold and colchicine, another series of experiments was per- 
formed in which gold or colchicine was incubated with lysates from granules of 
5 M 106 human leukocytes. The results of these experiments are given in Table 
II. Under these conditions colchicine, even at a concentration as high as 10-~M, 
was ineffective in preventing the granule lysates from causing the release of 3~S 
from labeled cartilage. Gold, however, at  10-4M  and 10-SM,  inhibited signifi- 
cantly cartilage destruction (79% and 63%, respectively) induced by human 
granule lysates. 
Comparison  of  Phagocytic  and  Nonphagocytic  Release of  Enzymes  and  the 
Effect of Serum.--The supernatant from cells preincubated with a suspension of 
AHGG (phagocytic enzyme release) for 2 h at 37°C  (after centrifugation) was 14  0.300 
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Fro. 3. Requirement of AHGG for the selective  nonphagocytic release of neutral protease 
and 13-G from human leukocytes. 10 cartilage disks were incubated with 5 X  106 human leuko- 
cytes for 4 h  at 37°C  (pH 7.4). Cartilage coated with either AHGG or  nonaggregated HGG. 
Total ~aS in 10 cartilage disks equals 29,120 cpm. Lysates of 5  X  10 ~ cells contained 0.625 OD 
U  of fl-G activity and yielded a  change in OD/min  (366 nm) for  LDH  of  0.44.  Each  point 
is the Mean +SEM  of three separate determinations. 
added to 35S cartilage for an additional 4 h incubation. In the same experiment 
an equal number of cells was incubated directly ~ith AHGG-coated cartilage 
(nonphagocytic  release).  The  results  given in  Table II clearly indicate  that, 
there  was  a  three-  to  fourfold  increase  in  ~5S  release  during  nonphagocytic 
enzyme release  as compared to phagocytic release  (9,960  and 2,375  cpm, re- 
spectively). Cartilage coated with AHGG in the absence of cells released only 
390 cpm after a 4 h incubation at 37°C. Cells exposed to buffer for 2 h  (phago- 
cytic release  control)  release  very  little  neutral protease  (492  cpm after 4  h 
incubation of supernatant with 35S cartilage). Cell lysates from 5 X  10 ° leuko- 
cytes released  15,318  cpm or essentially  100%  of the  total  available counts, 
since acid hydrolysis released 15,490  cpm (Table III). Cells incubated directly 
with  AHGG-coated cartilage (nonphagocytic  conditions)  caused  69%  of the 
total counts to be released, while enzyme released during phagocytic conditions 
solubilized 15 % of the available 3~S (Table III). The release of fl-G was twofold 
greater under nonphagocytic conditions as compared to phagocytic conditions. 
DISCUSSION 
Recent  reports  have illustrated  two  important phenomena  relating  to  the 
role  of human  leukocytes in  the pathogenesis  of tissue  damage secondary to A.  ORONSKY~ L.  IGNARRO~ AND  R.  PERPER  467 
tissue  localization  of  antigen/antibody  complexes.  Firstly,  human  leukocytes 
contain enzymes, active at neutral pH, capable of destroying the chondronmco- 
protein matrix of cartilage  (1,  14)  and  collagen fibrils (15,  16).  Secondly,  lyso- 
somal  constitutents  are  released  when  human  leukocytes  phagocytose,  or at- 
tempt to phagocytose,  immune complexes (2,  3, 6,  17-19).  The purpose  of the 
TABLE  I 
F  ffect of Gold Sodium  Thiomalate  and Colchicine on Nonphagocytic  Release of Neutral Protease 
and ~-Glucuronidase from Human Leukocytes 
Neutral protease  /3-glucuronidase  (OD.  Experimental condition  (35S; cpm)  540 nm) 
Cartilage alone~  786  4-  10  -- 
Cartilage +  cells  7,116  4-  95  0.382  -4-  0.007 
Cartilage -b cells -t- gold (10  -4 M)  1,140  ~  25  0.391  4-  0.010 
C~rtilage +  cells -t- gold (10  -5 M)  2,934  4-  40  0.373  4-  0.008 
Cartilage +  cells +  gold (10  -6 M)  4,845  4-  90  0.360  4-  0.008 
Cartilage -t- cells -b colchicine (10  -4 M)  3,625  4-  50  0.175  4-  0.001 
Cartilage q- cells -b colchicine (10  -~ M)  5,430  4-  105  0.200  ±  0.010 
Cartilage q- cells q- colchicine (10  -6 M)  7,100  ±  95  0.340  4.  0.008 
* 5 X  106 human leukocytes incubated with cartilage for 4 h at 37°C in Hanks' BSS q- 1% 
glucose.  Cartilage coated with AHGG. 
Five cartilage disks/vial =  13,200 cpm. 
TABLE  II 
Effect  of Gold and  Colchicine on Release of 35S from  Labeled Cartilage  by Granule  Lysates  of 
Human Leukocytes 
Experimental* condition  ~S cpm:~ 
Cartilage alone 
Cartilage' -}- granule lysate 
Cartilage +  granule lysate +  colchicine (10  -3 M) 
Cartilage -[- granule lysate q- gold (10  -4 M) 
Cartilage q- granule lysate -9 gold (10  -5 M) 
cpm$ 
459  -4-  10 
14,727  :J=  150 
13,845  4.  100 
3,126  ±  20 
5,580  ±  85 
* Buffer in all experiments was Hanks' BSS containing 1% glucose; 5 )< 106 human leuko- 
cytes. 
:~ 10 cartilage disks/sample coated with AHGG =  23,200 cpm total (HC1). 468  RELEASE  OF  NEUTRAL  PROTEASE  FROM  HUMAN  LEUKOCYTES 
TABLE  III 
Nonphagocytic  and Phagocytic  Release of Neutral  Protease  and B-Glucuronidase from Human  Leakocytes 
Experimental 
condition 
Marker 
Cartilage§  (coated  I  3~S  (cpm) 
with  AHGG)  with-  I ~-G (OD) 
out cells  ] 
Xonphagocytic  release* 
Cartilage  (coated  i  a~S  (cpm) 
with  AHGG) +  ] ¢i'-G (OD) 
cells  [ 
Cell Iysate  +  i  ass  (cpm) 
cartilage  i[ ~-G  (OD) 
No serum 
390 
0.050 
9,960 
0.305 
15,318 
0.655 
10%* serum 
441 
0062 
1,91i 
0.318 
3,132 
0.677 
Preincubation 
condition 
Cells + 
buffer 
Cells  -- 
AHGG 
Phagocytic  release*  $ 
Marker  No serum 
a:'S (cpm)  492 
fl-G (OD)  0.021 
a~S  (cpm)  2,375 
G  (OD)  0.160  , 
10% 
serum 
542 
0.034 
440 
0.179 
* Buffer  in  all  experiments  was Itanks'  BSS  containing  1% glucose,  with  or without  70%  isologous  serum:  5  X  106 
human  leukocytes  were used. 
:~ After 2 h incubation  supernatant  was incubated  with five ass cartilage disks for another 4 h. 
§ Five  cartilage  dlsks/sample  -  75,490 cpm total  (HCI). 
present  studies  was  to  relate  the  above  findings  to  a  common  pathogenic 
mechanism  in  a  simple  in  vitro  model  where  neutral  protease  released  from 
viable leukocytes specifically degrade protein mucopolysaccharide matrix from 
intact cartilage. 
In a previous report, evidence was presented that release or solubilization of 
a'~'S-labeled anionic material from rabbit ear cartilage was a measure of enzymatic 
degradation  of  the  noncollagenous  chondromucoprotein  matrix  (1).  Such 
degradation could  be achieved with  enzymes obtained from granule lysates of 
human  but  not  guinea  pig  or  rabbit  leukocytes.  We  now  demonstrate  that 
human leukocytes overlying cartilage to which aggregated human IgG is bound, 
have  the capacity to release neutral  protease  that  subsequently degrade  the 
protein  mucopolysaccharide  matrix.  Cells  overlying  noncoated  cartilage  or 
cartilage coated with nonaggregated IgG do not release proteases and, therefore, 
no cartilage degradation is observed. Thus, enzyme release appears to be specific 
for aggregated  IgG.  A  similar,  but  no  greater,  effect  is  achieved  by  coating 
cartilage  with  washed precipitates  of aggregated IgG  preincubated  with  high 
titer human rheumatoid factor serum.  2 Several lines ot evidence indicate that the 
viability  of leukocytes was maintained  during  the  process of enzyme release 
and  cartilage  degradation.  During  the  course  of  a  5 h  incubation,  the  cells 
excluded  Trypan  blue  dye.  Noncoated  cartilage,  and  HGG-coated  cartilage 
were not degraded  in  the presence of overlying viable  cells,  and LDH  deter- 
minations  indicated  that  cytoplasmic  components were not  released  into the 
incubation  medium.  Finally,  the  kinetics  of  the  dose-response  experiments 
indicated  that  maximum  degradation  occurred  with  10  ;4  10 6  cells  and  a 
20ronsky, A. L., L. J. Ignarro, and R. J. Perper. Unpublished observations. A.  ORONSKY,  L. IGNARRO,  AND  R. PERPER  469 
further increase in cell number did not adversely affect the cartilage in spite of 
the fact that lysates of the same number of cells induced two to three times 
greater destruction of matrix. 
When incubation time was varied, release of ~-G from cells began immedi- 
ately but was essentially complete at 2 h. These data confirm previous observa- 
tions that maximal enzyme release occurs 1-2 h after initiation of phagocytosis 
(20).  Cartilage matrix degradation (release of ~5S) continued in a linear fashion 
up to at least 4 h, indicating that the neutral protease was relatively stable 
after being released and remained active under the experimental conditions. 
The release of fl-G and neutral protease was compared under phagocytic and 
nonphagocytic experimental conditions. Release of enzymes was two to four 
times greater  during nonphagocytic release,  which is in  agreement with the 
data of Henson  (6)  who showed that complexes fixed to nonphagocytosable 
surfaces were more effective in inducing enzyme release from leukocytes than 
when such complexes are in suspension  (21).  Although complete evidence is 
lacking as  to  the fate of all antigen/antibody complexes in joint fluid from 
rheumatoid arthritics, some are removed by phagocytosing synovial lining cells 
and cells suspended in the synovial fluid (22, 23). In addition, it is also possible 
that some complex becomes fixed to the surface of the articular cartilage. In 
support of this is the observation that in experimentally-induced synovitis in 
rabbits,  antigen/antibody complexes are  retained preferentially in the intra- 
articular space and probably bound to articular cartilage (24). It is reasonable 
to suspect, from these observations, that in human arthritic disease immune 
complexes could bind to articular cartilagenous structures. The cartilage would 
then be susceptible to the degradative action of neutral proteases released from 
leukocytes under nonphagocytic enzyme release conditions. 
Release of lysosomal enzymes cannot be attributed to the presence of plate- 
lets since these cells did not release detectable amounts of/3-G or neutral pro- 
tease under the experimental conditions described. Phagocytic and nonphago- 
cytic release of lysosomal enzymes did not require the intact complement system 
since  enzyme release  was  observed  with  or  without  fresh  isologous serum. 
Similar findings were reported by Weissmann et al. (2). 
By the use of appropriate inhibitors it was possible to distinguish two events 
comprising the process by which viable cells, adhering to cartilage, destroy the 
protein mucopolysaccharide matrix. Both gold sodium thiomalate and colchicine 
inhibited cartilage destruction during nonphagocytic enzyme release by human 
leukocytes. However, the mechanisms of action of these two compounds were 
completely  different.  Colchicine  inhibited  the  release  of  enzymes  (neutial 
protease, fl-G) but not the activity of the released enzymes, since it was virtually 
ineffective in preventing the cartilage destruction by cell lysates. In contrast, 
gold inhibited the activity of the released neutral protease without affecting 
the release process,  as evidenced by the finding that gold inhibited cartilage 
destruction without affecting the release of/3-G. These results might explain 470  RELEASE  OF  NEUTRAL  PROTEASE  EROM  HUMAN  LEUKOCYTES 
the  therapeutic effect of gold  salts  in  the  treatment  of rheumatoid arthritis 
since it has been shown that gold salts,  when administered parenterally, ac- 
cumulate in  the  granules of both synovial lining cells and infiltrating leuko- 
cytes (25, 26). 
Isologous human serum (10%), like gold, inhibited neutral protease activity 
without affecting the enzyme release process. Perhaps this might argue against 
the relevance of neutral protease activity in vivo since vascular permeability is 
increased in  most  inflammatory arthritides,  and  at  least  some plasma  con- 
stituents would be expected to contaminate the joint fluid. However, it should 
be noted that a high degree of variability exists with regard to the concentra- 
tions of proteins and other constituents in joint fluids under pathological as well 
as normal conditions (27). It therefore would be important to conduct various 
experiments designed to examine the influence of synovial fluids on the release 
and activity of enzymes from human leukocytes. Experiments of this type are 
presently under way in our laboratories. 
SUMMARY 
The granule fraction of human leukocytes contains neutral protease capable 
of degrading the noncollagenous protein nmcopolysaccharide matrix of cartilage 
at neutral pH in physiological salt solution.  Cartilage degradation was moni- 
tored by quantitating  the release of 35S from labeled rabbit ear cartilage. De- 
gradation of cartilage matrix occurs when intact viable human leukocytes are 
incubated  with  cartilage  opsonized with  aggregated  human  gamma  globulin 
(AHGG). During a similar 4 h incubation period cells did not degrade uncoated 
cartilage or cartilage coated with nonaggregated gamma globulin. Cells remain 
viable  during  the  enzyme release process as  evidenced by the  absence  of a 
cytoplasmic enzyme marker (lactic dehydrogenase) in the supernatant and dye 
exclusion studies. The release of 35S from labeled cartilage by human leukocytes 
in  the  presence  of cartilage  coated with AHGG (nonphagocytic enzyme re- 
lease) was compared with the cartilage degrading activity of the supernatant 
from  the  same  number  of  cells  preincubated  with  a  suspenslon  of  AHGG 
(phagocytic enzyme release). Nonphagocytic enzyme release by 5  X  l0  G  cells 
provoked two to four times more 35S and/5-glucuronidase  (/3-G) release from 
cartilage than phagocytic enzyme release conditions./3-glucuronidase was used 
as an indicator of the release of lysosomal granule enzymes. 
By the use of selected pharmacological agents it was possible to dissociate 
the enzyme release process from intrinsic enzyme (neutral protease) activity. 
Neutral protease and ~-G release by human  cells in the presence of AHGG- 
coated cartilage was inhibited by 10-SM  colchicine, whereas the protease ac- 
tivity, but not the release process, was inhibited by 10-SM gold thiomalate and 
10%  human  serum.  It is  suggested  that  the release of a  cartilage degrading 
neutral protease by viable human  cells  when exposed to AHGG might be a 
relevant model for the study of cartilage destruction as it occurs in rheumatoid 
a rthritis. A.  ORONSKY~ L.  IGNARRO~ AND R.  PERPER  471 
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